MX2010002295A - Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas. - Google Patents

Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.

Info

Publication number
MX2010002295A
MX2010002295A MX2010002295A MX2010002295A MX2010002295A MX 2010002295 A MX2010002295 A MX 2010002295A MX 2010002295 A MX2010002295 A MX 2010002295A MX 2010002295 A MX2010002295 A MX 2010002295A MX 2010002295 A MX2010002295 A MX 2010002295A
Authority
MX
Mexico
Prior art keywords
solid forms
benzothiazol
isoxazol
morpholin
imidazo
Prior art date
Application number
MX2010002295A
Other languages
English (en)
Spanish (es)
Inventor
Alan Schwartz
Shripad Bhagwat
Valeriya N Smolenskaya
Stephan D Parent
Wei Lai
Melanie J Roe
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of MX2010002295A publication Critical patent/MX2010002295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
MX2010002295A 2007-09-19 2008-09-19 Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas. MX2010002295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99463507P 2007-09-19 2007-09-19
PCT/US2008/010884 WO2009038757A2 (en) 2007-09-19 2008-09-19 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (1)

Publication Number Publication Date
MX2010002295A true MX2010002295A (es) 2010-03-22

Family

ID=40468693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002295A MX2010002295A (es) 2007-09-19 2008-09-19 Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.

Country Status (20)

Country Link
US (2) US8883783B2 (show.php)
EP (1) EP2201018B1 (show.php)
JP (1) JP5462168B2 (show.php)
KR (2) KR101572701B1 (show.php)
CN (1) CN101868465B (show.php)
AR (1) AR068528A1 (show.php)
AU (1) AU2008302744B2 (show.php)
BR (1) BRPI0816904B8 (show.php)
CA (1) CA2696776C (show.php)
CY (1) CY1117583T1 (show.php)
DK (1) DK2201018T3 (show.php)
ES (1) ES2573292T3 (show.php)
HR (1) HRP20160520T1 (show.php)
HU (1) HUE027982T2 (show.php)
IL (1) IL203926A (show.php)
MX (1) MX2010002295A (show.php)
PL (1) PL2201018T3 (show.php)
SI (1) SI2201018T1 (show.php)
TW (1) TWI437988B (show.php)
WO (1) WO2009038757A2 (show.php)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820657B2 (en) 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
SI2201018T1 (sl) 2007-09-19 2016-09-30 Ambit Biosciences Corporation Trdne oblike, ki obsegajo N-(5-terc.butil-izoksazol-3-il)-N'-(4-Y7-(2- morfolin-4-il-etoksi)imidazoY2,1-B"Y 1,3"benzotiazol-2-ilfenil)sečnina, njihove sestave in uporabe z njimi
EP2596795A1 (en) * 2007-11-08 2013-05-29 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
ES2681529T3 (es) 2009-03-23 2018-09-13 Ambit Biosciences Corporation Métodos de tratamiento utilizando terapia de combinación
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2496584B1 (en) * 2009-11-05 2016-09-21 Ambit Biosciences Corporation Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513257B (zh) * 2013-09-26 2017-02-15 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
WO2016133194A1 (ja) 2015-02-20 2016-08-25 第一三共株式会社 がんの併用治療法
CN109251181B (zh) * 2017-07-13 2021-08-31 广东东阳光药业有限公司 取代脲衍生物的盐及其在药物中的应用
AU2018304177B2 (en) * 2017-07-18 2023-11-02 Basf Se Methods for the purification of L-glufosinate
CN110763544A (zh) * 2019-09-20 2020-02-07 南京聚谱检测科技有限公司 一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) * 2020-02-20 2020-07-14 广东电科院能源技术有限责任公司 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (show.php) 1964-02-29
NL129626C (show.php) 1964-04-08
US3210370A (en) 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
JPS58109491A (ja) * 1981-12-23 1983-06-29 Yamanouchi Pharmaceut Co Ltd ２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体
US4464384A (en) 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
DK0571253T3 (da) 1992-05-19 1999-07-19 Adir Benzimidazolderivater med antidiabetisk og antiblodpladekoagulerende virkning
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
JP3178843B2 (ja) 1995-03-13 2001-06-25 日研化学株式会社 イミダゾチアゾール化合物
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
CA2315717C (en) 1997-12-22 2011-02-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU2001278875B2 (en) 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030143199A1 (en) 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
US20040127719A1 (en) 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
CA2506796A1 (en) 2002-11-25 2004-06-10 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
JP2006516139A (ja) 2002-12-18 2006-06-22 マリンクロッド・インコーポレイテッド ヘテロアリールアセトアミド化合物の合成
KR100647583B1 (ko) 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
US7820657B2 (en) * 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
SI2201018T1 (sl) 2007-09-19 2016-09-30 Ambit Biosciences Corporation Trdne oblike, ki obsegajo N-(5-terc.butil-izoksazol-3-il)-N'-(4-Y7-(2- morfolin-4-il-etoksi)imidazoY2,1-B"Y 1,3"benzotiazol-2-ilfenil)sečnina, njihove sestave in uporabe z njimi
EP2596795A1 (en) 2007-11-08 2013-05-29 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Also Published As

Publication number Publication date
CN101868465A (zh) 2010-10-20
JP5462168B2 (ja) 2014-04-02
ES2573292T3 (es) 2016-06-07
HUE027982T2 (en) 2016-11-28
PL2201018T3 (pl) 2016-11-30
ES2573292T9 (es) 2016-07-08
WO2009038757A2 (en) 2009-03-26
EP2201018B1 (en) 2016-03-16
US8883783B2 (en) 2014-11-11
EP2201018A2 (en) 2010-06-30
CA2696776A1 (en) 2009-03-26
HRP20160520T1 (hr) 2016-07-29
AU2008302744B2 (en) 2014-01-30
US20090131426A1 (en) 2009-05-21
KR20150104231A (ko) 2015-09-14
WO2009038757A3 (en) 2009-05-28
KR101572701B1 (ko) 2015-11-27
BRPI0816904B1 (pt) 2021-08-10
US9585892B2 (en) 2017-03-07
AR068528A1 (es) 2009-11-18
DK2201018T3 (en) 2016-05-17
TWI437988B (zh) 2014-05-21
CA2696776C (en) 2015-12-15
BRPI0816904A2 (pt) 2015-03-17
CY1117583T1 (el) 2017-04-26
TW200920360A (en) 2009-05-16
KR20100061734A (ko) 2010-06-08
AU2008302744A1 (en) 2009-03-26
CN101868465B (zh) 2013-12-25
IL203926A (en) 2016-02-29
SI2201018T1 (sl) 2016-09-30
BRPI0816904B8 (pt) 2021-12-07
US20150238499A1 (en) 2015-08-27
JP2010539237A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
MX2010002295A (es) Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
UA95940C2 (uk) Азаіндоли як інгібітори кіназ януса
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
NI201200072A (es) Métodos y composiciones para tratar cáncer
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
ZA200710379B (en) Pyrrolopyridines useful as inhibitors of protein kinase
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
UA85559C2 (en) Aminobenzophenone compounds
WO2007135026A3 (de) Substituierte pteridine als therapeutika
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
SE0203304D0 (sv) Novel Coumpounds
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
NO20084177L (no) Substituerte Imidazo[2,1-B]thiazolforbindelser og deres anvendelse for produksjon av legemidler
ATE512968T1 (de) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
FG Grant or registration